Xenon Pharmaceuticals' chief medical officer sold 1,410 shares worth $78,000 on March 13, 2026, representing a routine RSU vesting and sell-to-cover transaction. The stock has surged 55% following positive Phase 3 trial results for its lead candidate azetukalner and a $750 million capital raise. Despite significant losses ($345.9M in 2025), the well-capitalized biotech remains a binary bet on its neurological drug pipeline.

Xenon Pharmaceuticals priced an upsized public offering of 10.5 million common shares at $57.00 per share and pre-funded warrants, expected to raise approximately $650 million gross proceeds. The offering is expected to close on March 12, 2026, with J.P. Morgan, Jefferies, and other major underwriters managing the deal.

Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.

Xenon Pharmaceuticals granted 39,250 share options to five new non-officer employees, with options vesting over four years and an exercise price of $44.61 per share.

Xenon Pharmaceuticals granted 24,200 share options to six new non-officer employees, with an exercise price of $30.54 per share, vesting over four years.

Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units. The share options have an exercise price of $38.28 per common share and vest over four years, while the performance share units will vest based on the achievement of certain predefined milestone-based objectives over an approximately three-year period.

The epilepsy market is expected to grow due to an increase in disease prevalence and the launch of emerging therapies. The market is segmented into partial epilepsy, chronic focal epilepsy, and drug-resistant epilepsy, with various treatment options and pipeline drugs.

Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.

Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV.